NasdaqCM - Nasdaq Real Time Price USD

BioXcel Therapeutics, Inc. (BTAI)

1.7750

-0.0750

(-4.05%)

At close: 4:00:01 PM EDT

1.7800

+0.00

+(0.28%)

After hours: 4:43:57 PM EDT

BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioXcel Therapeutics ( NASDAQ:BTAI ) Full Year 2024 Results Key Financial Results Net loss: US$59.6m (loss narrowed by...

Simply Wall St. last month

BTAI
-4.05%
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 18.12% and 144%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

BTAI
-4.05%
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: B

GlobeNewswire last month

BTAI
-4.05%
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight

Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.

Zacks last month

BTAI
-4.05%

DGX

TEM
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI® in the home setting Company has $35M of cash following closing of recent equity financing NEW HAVEN, Conn., March 11, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that, following the successful raise of $14 million gross proceeds in

GlobeNewswire last month

BTAI
-4.05%
Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week

We recently compiled a list of the 10 Micro-, Small-Cap Firms Were Last Week’s Top Performers. In this article, we are going to take a look at where BioXcel Therapeutics, Inc. (NASDAQ:BTAI) stands against the other stocks. Micro- and small-cap companies dominated the stock market last week, clocking in impressive gains on the back of a […]

Insider Monkey last month

BTAI
-4.05%

^RUT
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Data to support potential sNDA submission for label expansion of IGALMI® in the home setting Topline data expected in second half of 2025 NEW HAVEN, Conn., March 07, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced it has reached 33% enrollment in its 200-patient SERENITY At-Home trial. The pivotal Phase 3 trial is designed to evaluate the safety o

GlobeNewswire last month

BTAI
-4.05%
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?

ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

SCPH

BTAI
-4.05%
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced the closing of its previously announced registered direct offering of 4,000,000 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Wa

GlobeNewswire last month

BTAI
-4.05%
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

BTAI
-4.05%

IGMS
BioXcel Therapeutics Announces $14 Million Registered Direct Offering

NEW HAVEN, Conn., March 03, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale in a registered direct offering of 4,000,000 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or commo

GlobeNewswire last month

BTAI
-4.05%
BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia

FDA concludes site inspection is closed under 21 C.F.R.20.64(d)(3); Voluntary Action Indicated Company believes this further supports reliability of data from TRANQUILITY II trial of BXCL501 NEW HAVEN, Conn., March 03, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the U.S. Food and Drug Administration (FDA) has concluded that the inspection

GlobeNewswire last month

BTAI
-4.05%
BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

NEW HAVEN, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). As previously disclosed, on

GlobeNewswire 2 months ago

BTAI
-4.05%
BioXcel Therapeutics Announces Reverse Stock Split

NEW HAVEN, Conn., Feb. 06, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will effect a 1-for-16 reverse stock split of its common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on February 7, 2025, with the company’s common stock expected to begin trading on a split-adjusted basis at the opening of the mar

GlobeNewswire 2 months ago

BTAI
-4.05%
BioXcel Therapeutics Provides Clinical and Business Update

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Developed plans for TRANQUILITY In-Care Phase 3 trial of BXCL501 for agitation associated with Alzheimer’s dementia Enhanced operational and financial flexibility through existing credit amendment Strengthened strategic leadership with recent Board appointments NEW HAVEN, Conn., Feb. 05, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (

GlobeNewswire 2 months ago

BTAI
-4.05%
BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade

BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 4 months ago

BTAI
-4.05%
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the pricing of an underwritten public offering of 5,600,000 shares of its common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants to purchase up to 5,600,000 shares of Common Stock, and, in lieu the

GlobeNewswire 5 months ago

BTAI
-4.05%
BioXcel Therapeutics Announces Proposed Public Offering

NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of shares of its common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants to purchase shares of Common Stock, and, in lieu thereof to certain inv

GlobeNewswire 5 months ago

BTAI
-4.05%
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...

BioXcel Therapeutics Inc (BTAI) reports significant progress in pivotal trials and improved financial metrics despite revenue challenges.

GuruFocus.com 5 months ago

BTAI
-4.05%
Q3 2024 BioXcel Therapeutics Inc Earnings Call

Q3 2024 BioXcel Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 5 months ago

BTAI
-4.05%

Performance Overview

Return	BTAI	S&P 500 (^GSPC)
YTD	-70.34%	-4.72%
1-Year	-95.63%	+11.67%
3-Year	-99.15%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

BioXcel Therapeutics Announces Reverse Stock Split

BioXcel Therapeutics Provides Clinical and Business Update

BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...

Q3 2024 BioXcel Therapeutics Inc Earnings Call

Performance Overview